interviews | May 13, 2026
AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
We are building an AI-native operating system for pharma sales and distribution
We are building an AI-native operating system for pharma sales and distribution
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
Subscribe To Our Newsletter & Stay Updated
